NM_000039.3(APOA1):c.494T>C (p.Leu165Pro) AND Cardiovascular phenotype

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Jun 22, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV003341793.2

Allele description [Variation Report for NM_000039.3(APOA1):c.494T>C (p.Leu165Pro)]

NM_000039.3(APOA1):c.494T>C (p.Leu165Pro)

Genes:

APOA1-AS:APOA1 antisense RNA [Gene - OMIM - HGNC]
APOA1:apolipoprotein A1 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

11q23.3

Genomic location:

Preferred name:

NM_000039.3(APOA1):c.494T>C (p.Leu165Pro)

HGVS:

NC_000011.10:g.116836118A>G
NG_012021.1:g.6505T>C
NM_000039.3:c.494T>CMANE SELECT
NM_001318017.2:c.494T>C
NM_001318018.2:c.494T>C
NM_001318021.2:c.167T>C
NP_000030.1:p.Leu165Pro
NP_000030.1:p.Leu165Pro
NP_001304946.1:p.Leu165Pro
NP_001304947.1:p.Leu165Pro
NP_001304950.1:p.Leu56Pro
NP_001304950.1:p.Leu56Pro
LRG_767t1:c.494T>C
LRG_767:g.6505T>C
LRG_767p1:p.Leu165Pro
NC_000011.9:g.116706834A>G
NM_000039.1:c.494T>C
NM_001318021.1:c.167T>C
NR_126362.1:n.2A>G

Protein change:

L165P

Molecular consequence:

NM_000039.3:c.494T>C - missense variant - [Sequence Ontology: SO:0001583]
NM_001318017.2:c.494T>C - missense variant - [Sequence Ontology: SO:0001583]
NM_001318018.2:c.494T>C - missense variant - [Sequence Ontology: SO:0001583]
NM_001318021.2:c.167T>C - missense variant - [Sequence Ontology: SO:0001583]
NR_126362.1:n.2A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Cardiovascular phenotype
Identifiers:: MedGen: CN230736

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004051269	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Jun 22, 2023)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004051269

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Jun 22, 2023)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV004051269.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.L165P variant (also known as c.494T>C), located in coding exon 3 of the APOA1 gene, results from a T to C substitution at nucleotide position 494. The leucine at codon 165 is replaced by proline, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 1, 2024

ClinVar

Relating variation to medicine